GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InNexus Biotechnology Inc (GREY:IXSBF) » Definitions » Profitability Rank

InNexus Biotechnology (InNexus Biotechnology) Profitability Rank : 0 (As of Mar. 2011)


View and export this data going back to . Start your Free Trial

What is InNexus Biotechnology Profitability Rank?

InNexus Biotechnology has the Profitability Rank of 0.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

InNexus Biotechnology's Operating Margin % for the quarter that ended in Mar. 2011 was %. As of today, InNexus Biotechnology's Piotroski F-Score is 0.


Competitive Comparison of InNexus Biotechnology's Profitability Rank

For the Biotechnology subindustry, InNexus Biotechnology's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InNexus Biotechnology's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InNexus Biotechnology's Profitability Rank distribution charts can be found below:

* The bar in red indicates where InNexus Biotechnology's Profitability Rank falls into.



InNexus Biotechnology Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

InNexus Biotechnology has the Profitability Rank of 0.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

InNexus Biotechnology's Operating Margin % for the quarter that ended in Mar. 2011 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2011 ) / Revenue (Q: Mar. 2011 )
=-0.316 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

InNexus Biotechnology has an F-score of 0. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


InNexus Biotechnology Profitability Rank Related Terms

Thank you for viewing the detailed overview of InNexus Biotechnology's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


InNexus Biotechnology (InNexus Biotechnology) Business Description

Traded in Other Exchanges
N/A
Address
1055 West Georgia Street, 1500 Royal Centre, Vancouver, BC, CAN, V6E 4N7
InNexus Biotechnology Inc is engaged in commercializing the next generation of monoclonal antibodies based on its DXL technology, which improves the potency of existing antibody products while opening new markets and disease applications.

InNexus Biotechnology (InNexus Biotechnology) Headlines

No Headlines